Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2009

View Archived Issues

GABA-A alpha5 inverse agonists show potential in the treatment of cognitive dysfunction

Preclinical evaluation of novel selective Nav1.8 modulators as potential analgesic agents

Sanofi-aventis signs licensing agreement for Wellstat's insulin sensitizer PN-2034

Teva reports results from phase III trial of MediWound's Debrase for burns

Affiris reports results from phase I studies of its two Alzheimer's disease vaccines

BLISS-52 study shows significant benefit with belimumab in SLE

Further clinical data on dapagliflozin presented at the World Diabetes Congress

Non-selective opioid modulator RDC-5768 reduces behavioral effects of drugs of abuse

Rolapitant similar to ondansetron in treating postoperative nausea and vomiting

Aminophylline reverses midazolam sedation in healthy volunteers

AMR-MCH-14 reduces food intake and body fat in preclinical model of obesity

The GnRH antagonist TAK-38 has potential for the treatment of endometriosis

SciClone enrolls first patient in phase II SCV-07 trial in HCV

FDA grants fast track designation to MacuSight's ocular sirolimus drug Perceiva for DME

FDA accepts for review ProStrakan's refiled NDA for Cellegesic for chronic anal fissures

Teijin signs exclusive sublicense agreement for TMX-67 with Ipsen and Menarini

Northwest reports follow-up data from phase I and I/II trials of DCVax-Brain in GBM

Sosei presents update on clinical development of NVA-237 and QVA-149 for COPD

Millennium initiates phase II trial of bortezomib in non-GCB diffuse large B-cell lymphoma

Chugai and Taisho file NDA in Japan for eldecalcitol for osteoporosis

Isis reports results from phase II study of ISIS-113715 in type 2 diabetes

Arpida withdraws MAA for iclaprim for cSSTI following CHMP's negative opinion

Dainippon Sumitomo Pharma and Sepracor successfully complete acquisition

Novartis granted E.U. approval for Exforge HCT for high blood pressure

Boehringer Ingelheim discloses CB2 receptor agonists for the treatment of pain

Merck KGaA describes glucokinase activators for the treatment of diabetes

University of California claims IRES inhibitors for the treatment of HCV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...